Licensing status

Publication and contact information

Ophthalmic disease


ATPase Na+/K+ transporting a2 polypeptide (ATP1A2)

In vitro and rabbit studies have identified selective inhibitors of ATP1A2 that could be useful for treating glaucoma. In vitro studies identified perhydro-1,4-oxazepine derivatives of digoxin that inhibited ATP1A2 with higher selectivity than digoxin. In a rabbit model of glaucoma, an eye drop formulation of the lead ATP1A2 inhibitor was more effective at preventing chemical-induced elevation of intraocular pressure than digoxin. Next steps could include long-term animal safety studies on the eye drop formulation of the ATP1A2 inhibitor.

SciBX 7(28); doi:10.1038/scibx.2014.835
Published online July 24, 2014

Patent pending; available for licensing from Yeda Research and Development Company Ltd., the technology commercialization arm of the Weizmann Institute of Science

Katz, A. et al. J. Biol. Chem.; published online June 10, 2014;
Contact: Steven J.D. Karlish, Weizmann Institute of Science, Rehovot, Israel